Introduction
Infections caused by MRSA are associated with substantial morbidity and mortality and continue to increase in incidence. 1 While vancomycin remains the treatment of choice for many severe infections caused by MRSA, treatment failure and elevated MICs are leading to an increased use of alternative agents. [2] [3] [4] [5] [6] Daptomycin and linezolid are frequently recommended and used as alternatives to vancomycin for severe MRSA infections; 4 however, these antibiotics are limited by potentially inadequate concentrations at certain body sites and significant adverse reactions. 4, 7 Ceftaroline is a cephalosporin with potent activity against MRSA and many common Gram-negative organisms. 8 Due to its activity against MRSA and favourable side effect profile, ceftaroline is sometimes used as an alternative agent for treatment of complicated infections caused by Staphylococcus aureus and other organisms that require prolonged treatment durations. Phase III trials of ceftaroline in the treatment of communityacquired pneumonia and complicated skin and skin structure infections assessed maximum treatment durations of 7 and 14 days, respectively. [9] [10] [11] [12] [13] [14] Data evaluating ceftaroline when used for longer durations are limited and are mostly comprised of case series. [15] [16] [17] [18] [19] [20] [21] Several recent non-comparative, retrospective studies have identified a higher than anticipated risk of neutropenia in patients receiving .7 days of ceftaroline. [22] [23] [24] [25] b-Lactams are known to cause neutropenia; however, the reported incidence of .10% in these studies is concerning. 26, 27 Owing to lack of comparative data in these studies, it is difficult to ascertain whether ceftaroline is responsible for this unexpectedly high incidence of neutropenia or if underlying patient or clinical characteristics may be culpable. This study sought to evaluate the V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
incidence of neutropenia in patients receiving prolonged treatment with ceftaroline compared with five other commonly used antistaphylococcal antibiotics.
Patients and methods

Study setting and design
This retrospective cohort study included patients admitted from April 2011 to September 2017 at a six-hospital health system in the greater Portland, Oregon area. All hospitals are considered community or community teaching hospitals. Two groups were compared: the ceftaroline group and the control group, which included patients who received cefazolin, daptomycin, linezolid, nafcillin or vancomycin.
Inclusion and exclusion criteria
Adult patients that received inpatient treatment with ceftaroline, cefazolin, daptomycin, linezolid, nafcillin or vancomycin were screened for inclusion. We previously evaluated 77 patients who received 7 days of consecutive ceftaroline therapy and found that neutropenia only developed in those receiving 14 days. 25 Based on this information, we chose to exclude those patients with inpatient courses ,14 consecutive days in duration. In addition, those with active malignancy, with no baseline or no follow-up blood laboratories, or with neutropenia within 24 h of antibiotic initiation were excluded.
Definitions
Neutropenia was defined as an absolute neutrophil count (ANC) ,1500 cells/mm 3 . Consecutive neutropenia was defined as neutropenia on 2 or more consecutive days. Moderate neutropenia was defined as an ANC ,1000 cells/mm 3 . Severe neutropenia was defined as an ANC ,500 cells/mm 3 . Charlson comorbidity index scores were calculated as previously described. 28 The ANC nadir was calculated as the lowest ANC during antibiotic treatment. The primary infecting organism was the organism identified on microbiology cultures for which the antibiotic was most likely selected.
Outcomes
The primary outcome was the development of neutropenia during antibiotic therapy. Secondary outcomes included the development of consecutive neutropenia, moderate neutropenia, severe neutropenia and discontinuation of antibiotic due to neutropenia. Consecutive neutropenia was chosen as an outcome to identify patients that had more than a single day of transient neutropenia. In patients who met the primary outcome, the Naranjo Adverse Drug Reaction Probability Scale 29 was used to assess the likelihood that the antibiotic was the cause.
Statistical analysis
With an estimated 18% incidence of neutropenia in the ceftaroline group, 22, 24, 25 we calculated a control group of 460 patients was required to have 80% power to detect a difference if the incidence of neutropenia was 5% in the control group. 30 Normality of data was assessed visually and by the Shapiro-Wilk test. Data were compared between the ceftaroline group and the control group using Fisher's exact test, v 2 test, Student's t-test and Wilcoxon rank-sum test, as appropriate. A multivariate logistic regression model was constructed to evaluate the impact of ceftaroline receipt on development of neutropenia. Covariates were included in this model if found to have a P , 0.10 on univariate analysis with P , 0.10 set for retention in the final model. Model fit was assessed by the Tukey-Pregibon link test. This same methodology was replicated for the secondary outcomes. The incidence of neutropenia between individual antibiotics was also examined using multivariate modelling as described. Finally, as we anticipated that substantial differences in clinical characteristics between antibiotic groups might exist, we performed propensity score analysis using inverse probability weights with regression adjustment. This analysis allows for covariate balance between treatment groups while simultaneously modelling the treatment outcome and preserving the whole data set. 31, 32 After the propensity score weighting, the balance between treatment groups was assessed by examination of raw and weighted differences and by an overidentification test. All analyses were performed in Stata version 14 (Stata-Corp, College Station, TX, USA).
Results
Over the study period, 219553 courses of study antibiotics were received. However, only 753 met criteria for study inclusion with 53 patients receiving ceftaroline and 700 receiving control antibiotics ( Figure 1 ). Substantial differences were found between the control and ceftaroline groups, including the length of stay prior to initiating the study drug, primary infecting pathogen and infectious diagnosis ( Table 1) .
A total of 36 (4.8%) patients met criteria for neutropenia. All patients had a Naranjo Adverse Drug Reaction Probability Scale score of 3 or 4 indicating that the drug was a possible cause of neutropenia; as all patients were experiencing an acute or chronic infectious process during the time of drug administration, an alternate explanation for neutropenia was consistently possible. Additionally, 11% (4 of 36) of the neutropenic patients had previous neutropenic episodes in the preceding months. The median time from drug initiation to neutropenia was 20 days (25th-75th percentile, 15-29 days) and was similar regardless of drug (P " 0.28). Neutropenia developed in 4.4% of those who received ,21 days of therapy and in 5.3% of those who received 21 days (P " 0.56). In the ceftaroline group, neutropenia developed in 20.0% who received ,21 days of therapy and in 15.2% of those who received 21 days. Interestingly, the ANC nadir of those qualifying as neutropenic appeared to be a result of lower baseline ANC in addition to the decrease in ANC during antibiotic therapy (Table 2 ). Upon evaluation of drug dosing and frequency, neutropenia appeared to be dose independent for all drugs. Only three of the neutropenic patients (3 of 36, 8.3%) concurrently developed thrombocytopenia (platelets ,100%10 All outcomes occurred more frequently in the ceftaroline group (Table 3) . After controlling for covariates identified in univariate analysis, receipt of ceftaroline continued to be associated with the development of neutropenia (Table 4) . After controlling for these covariates, cefazolin was identified as having the lowest risk of neutropenia. Besides ceftaroline, the only other antibiotic to have a significantly greater incidence of neutropenia compared with cefazolin was nafcillin (adjusted OR 4.4, P " 0.029). Using these same predictors, but with consecutive or moderate neutropenia as the outcome variable, a similarly greater risk was identified with the receipt of ceftaroline (adjusted OR 6.8, P , 0.001 and adjusted OR 7.0, P " 0.004, respectively). As the incidence of severe neutropenia was small (n " 5), further analysis of this outcome was not conducted.
Neutropenia with prolonged ceftaroline therapy JAC Propensity score weighting was conducted and covariates were well balanced between the ceftaroline and control groups. Analysis identified a higher incidence of neutropenia in those receiving ceftaroline (estimated incidence in the control and ceftaroline groups after propensity score weighting, 3.9% versus 13.1%, P " 0.049). When using consecutive or moderate neutropenia as the outcome variable, a higher incidence of neutropenia was found in those receiving ceftaroline (estimated incidence in the control and ceftaroline groups, 1.7% versus 10.7%, P " 0.037 and 1.1% versus 6.9%, P " 0.11, respectively).
Discussion
In patients already being treated for infection, the development of neutropenia is dangerous and may potentially lead to lifethreatening complications. 26 Acute neutropenia may be induced by a number of different factors including autoimmune diseases, genetic disorders, medications and even the presence of infection itself. 33 Specifically, b-lactams have been associated with neutropenia. It is postulated that the mechanism of b-lactam-induced neutropenia is due to two causes: an immune-mediated process, and direct damage to the myeloid cell line. [34] [35] [36] [37] Sparse data are available evaluating the incidence of neutropenia with receipt of the antibiotics included in the control group of this study. Youngster et al. 30 conducted a retrospective cohort analysis comparing the tolerability of nafcillin and cefazolin in outpatient treatment of MSSA infection. Median duration of therapy was 28 days (25th-75th percentile, 16-37 days) and 29 days (25th-75th percentile, 24-39 days) in the nafcillin and cefazolin groups, respectively. Neutropenia was identified in 8.4% and 3.3% of patients receiving nafcillin and cefazolin, which is similar to what was identified in our study (7.8% and 2.2% for nafcillin and cefazolin, respectively). Reports of neutropenia with daptomycin are virtually non-existent. 38 We identified four patients who developed neutropenia while receiving daptomycin; however, none qualified as moderate neutropenia and only one had consecutive neutropenia. The significance of this finding is unknown but likely of limited value. A study from 1991 described a 12% incidence (6 of 50) of neutropenia in patients receiving vancomycin (duration of therapy ranged from 15 to 28 days) in a cardiothoracic surgical ward. 39 Similarly, Pai et al. 40 identified a 12% (14 of 114) incidence of neutropenia in patients receiving outpatient vancomycin for a duration of 32+29 days. In contrast to these reports, we only identified neutropenia in 3.2% of patients receiving vancomycin. Although the study by Pai et al. 40 included outpatients that received longer durations of vancomycin therapy, it remains unclear why this difference between studies exists. While the inhibitory effect of linezolid on platelets has been known for some time, 41 case reports associating linezolid use to neutropenia are few 42, 43 with several reports suggesting no such association. 44, 45 No patients in our study were found to have neutropenia while receiving treatment with linezolid.
Several reports have previously associated prolonged ceftaroline treatment with the development of neutropenia. Zasowski et al. 46 reported a 1.4% incidence of neutropenia in 211 patients receiving ceftaroline for a minimum of 72 h with a median treatment duration of 11 days (25th-75th percentile, 5-15 days). It is interesting to note that the three patients who developed neutropenia did so on days 13, 15 and 20. 46 Dellabella et al. 23 found a 4% incidence of neutropenia when evaluating 74 patients with a median duration of ceftaroline therapy of 7 days (25th-75th percentile 4-14 days). Duration was not reported with respect to neutropenia but development of any identified adverse effects (neutropenia, other haematological toxicities and rash) was associated with a longer median treatment duration (17 versus 6.5 days, P " 0.002). 23 Adult inpatients receiving study antibiotics for ≥ 14 consecutive days n = 852
Excluded patients: n =99
Included in analysis n = 753
Ceftaroline: n =53 Cefazolin: n = 180 Daptomycin: n =41 Linezolid: n =28 Nafcillin: n = 103 Vancomycin: n = 348
Active malignancy: n =18 Baseline neutropenia: n =18 No baseline or no follow-up blood laboratories: n =63 Turner et al.
Subsequent case series were published with the express intent of examining incidence of neutropenia in patients treated with 7 days of ceftaroline therapy. LaVie et al. 24 identified an 18% incidence of neutropenia in 39 patients receiving ceftaroline therapy for 7 days with a median duration of therapy of 27 days (range 9-125 days). Of the seven patients who developed neutropenia, four developed severe neutropenia. Patients who developed neutropenia were more likely to be female (P " 0.030) and were Neutropenia with prolonged ceftaroline therapy JAC found to have a lower BMI (P " 0.24). 24 Furtek et al. 22 described a 10% incidence of neutropenia when evaluating 67 patients receiving 7 days of ceftaroline therapy. Five of the seven neutropenic patients developed severe neutropenia; two patients received 3 days of granulocyte colony stimulating factor to aid neutrophil recovery. Median duration of ceftaroline therapy was associated with development of neutropenia (15 versus 26 days, P " 0.048). When stratified by duration, the authors found a 14% incidence of neutropenia in patients receiving 14 days and a 21% incidence in those whose therapy extended .21 days. 22 Consistent with the results of these previous studies, our study identified a higher than anticipated incidence of neutropenia in patients receiving ceftaroline. We failed to identify gender or BMI as significant predictors of neutropenia in the ceftaroline or control groups in multivariate analysis. Contrary to these previous studies, only two patients who received ceftaroline developed severe neutropenia. The reason for this difference is not known but may be due to chance or a difference in clinical characteristics such as baseline ANC. In contrast to Furtek et al., 22 we did not identify a greater risk of neutropenia in those receiving greater durations of treatment. This was true for the ceftaroline and control groups. To our knowledge, this is the first study of neutropenia associated with ceftaroline to include a control group and attempt to control for confounding factors. We found that ceftaroline continued to be associated with a greater incidence of neutropenia after multivariate logistic regression and propensity score weighting. Several covariates were found to be associated with neutropenia including the presence of bone and joint infections. The reason for this association remains unclear. Rifampicin is commonly used concurrently with other antibiotic therapy in bone and joint infections and has been previously associated with the development of neutropenia; 47, 48 however, only five of the patients with neutropenia were concurrently receiving rifampicin. Removal of the bone and joint infection covariate from the multivariate models failed to alter the statistical significance of other associations and did not substantially alter the estimated ORs.
A substantial number of patients experienced transient neutropenia that occurred on just 1 day during antibiotic therapy (17 of 36, 47.2%) with subsequent resolution. Further study is needed; however, patients with transient neutropenia may be experiencing a normal infectious or other process that is unrelated to drug-induced neutropenia. Because of this possibility, we chose to evaluate consecutive neutropenia as a separate outcome. Analysis of this more stringent definition failed to alter the finding that ceftaroline was associated with neutropenia. Of peculiar interest is the low rate of antibiotic discontinuation identified in those with neutropenia (Table 3) . After reviewing clinician notes, we identified two possible causes: (i) some clinicians failed to acknowledge neutropenia in the patient record, whether deliberately or not, and (ii) some clinicians identified the antibiotic to be the most likely cause of neutropenia but chose to continue therapy as the risk of switching therapy was deemed riskier than the neutropenia. Many of these patients were treatment experienced with previous antibiotic courses and many were considered to be on last line (or next to last line) therapy; this may have influenced clinicians to continue therapy despite neutropenia.
Several substantial limitations are present in this study. First, as ceftaroline was used almost exclusively as salvage therapy in patients who failed previous therapies, substantial differences existed between treatment groups. We attempted to control for these differences; however, hidden selection bias may have persisted and influenced the results. Second, we included a control group of patients who received various antibiotics for similar indications. Comparison with additional antibiotics, including other b-lactams in addition to cefazolin and nafcillin, may have identified further results. The comparative antibiotics included in this study were chosen as they are most commonly used for treatment of staphylococcal infections and we felt this would limit heterogeneity. Third, we chose to exclude patients with durations ,14 days. While it may have been ideal to include all patients and stratify based on duration of therapy, we chose to exclude patients receiving shorter durations for several reasons: (i) some clinical trial evidence does exist for patients receiving 7-14 days of ceftaroline therapy; (ii) patients receiving 14 days of therapy were more likely to be on a stable, definitive antibiotic regimen for a documented infection, which allowed for comparison with the control group by infecting pathogen and infectious diagnosis; and (iii) the outcomes of patients receiving 14 days of therapy were less likely to be influenced by previous antibiotic therapies that were received. Finally, while our six-hospital system does include a burn unit, level 1 trauma centre and oncology services, our results may not extrapolate to other health systems as our system is primarily community-based and does not include several at risk populations.
The results of this study suggest that ceftaroline therapy of 14 days is associated with a greater incidence of neutropenia as compared with other antibiotics that are often used for treatment of staphylococcal infections. The efficacy and safety of ceftaroline for prolonged durations is unknown as data are limited. 18, 19, 21, 49, 50 Large prospective studies are needed to assess the efficacy of ceftaroline for prolonged durations as well as to assess safety. Despite this lack of data, we believe that ceftaroline will continue to be used for prolonged durations. We suggest that clinicians routinely monitor ANC and take appropriate action if neutropenia develops.
